Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17309549 | 0.86 | ALOX5 (0.42) | ALOX5SCN9APTGS2PTGS1MAP2K4 | |
| SCHEMBL2343451 | 0.85 | ALOX5 (0.41) | ALOX5SCN9APTGS2PTGS1MAP2K4 | |
| SCHEMBL2345988 | 0.85 | ALOX5 (0.44) | ALOX5SCN9APTGS2PTGS1MAP2K4 | |
| SCHEMBL22785825 | 0.84 | GCGR (0.51) | ALOX5SCN9APTGS2PTGS1NR3C1 | |
| SCHEMBL2340089 | 0.82 | ADORA1 (0.48) | SCN9AMAPK13GCGRMAPK12MAPK11 | |
| SCHEMBL14762690 | 0.80 | HMGCR (0.41) | ALOX5PTGS2PTGS1TRPV1GCGR | |
| SCHEMBL22785824 | 0.80 | GCGR (0.52) | ALOX5SCN9APTGS2PTGS1TRPV1 | |
| SCHEMBL14762686 | 0.80 | HMGCR (0.41) | ALOX5PTGS2PTGS1TRPV1GCGR | |
| SCHEMBL2344730 | 0.78 | PTGS2 (0.37) | ALOX5SCN9APTGS2PTGS1MAP2K4 | |
| SCHEMBL2346398 | 0.76 | ADORA2A (0.45) | SCN9AMAPK13GCGRMAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | claimed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | claimed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | claimed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| US-8034932-B2 | Hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitor; anticholesterol agents;dyslipidemia; chemical intermediate for rosuvastatin | ASTRAZENECA UK LIMITED (GB) | 2011-10-11 | — | — | US | disclosed |
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207903-A1 | Chemical Process | CYP2C9, CYP2B6, CYP7A1 | ALOX5 2554/4885SCN9A 955/4885PTGS2 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.